Table 3. Case-series analysis for thiazolidinediones: association between exposure to specific thiazolidinediones and fractures.
| Fracture Site | Exposure | Patient Years | n Fractures | Age-Adjusted Rate Ratio for Fracture (95% CI) |
| Fracture at any site | ||||
| Rosiglitazone (n = 1,356) | Unexposed periods | 12,772 | 1,139 | Baseline |
| Exposed periods | 3,180 | 543 | 1.49 (1.28–1.74)a | |
| Pioglitazone (n = 389) | Unexposed periods | 3,747 | 347 | Baseline |
| Exposed periods | 892 | 149 | 1.26 (0.95–1.68)a | |
| Foot, arm, wrist, or hand fracture | ||||
| Rosiglitazone (n = 675) | Unexposed periods | 6,446 | 539 | Baseline |
| Exposed periods | 1,564 | 211 | 1.30 (1.03–1.64) | |
| Pioglitazone (n = 188) | Unexposed periods | 1,748 | 158 | Baseline |
| Exposed periods | 446 | 61 | 1.43 (0.92–2.22) | |
| Hip fracture | ||||
| Rosiglitazone (n = 115) | Unexposed periods | 1,004 | 56 | Baseline |
| Exposed periods | 310 | 66 | 1.80 (1.03–3.15) | |
| Pioglitazone (n = 32) | Unexposed periods | 282 | 13 | Baseline |
| Exposed periods | 75 | 20 | 2.65 (0.81–8.70) | |
| Spine fracture | ||||
| Rosiglitazone (n = 53) | Unexposed periods | 492 | 33 | Baseline |
| Exposed periods | 132 | 24 | 3.13 (1.35–7.21) | |
| Pioglitazone (n = 11) | Unexposed periods | 107 | 7 | |
| Exposed periods | 18 | 4 | * | |
Patients exposed to both thiazolidinediones excluded.
a
Test for interaction (p = 0.47).
*: Insufficient outcomes to calculate rate ratio.